DOXORUBICIN EBEWE
2MG/ML INF CNC SOL 1X5ML
Announcement of launch, break or close-out of marketing of a medicinal product
Type of announcement | Effective date | Alternate medicines ? | Reason for interruption/cessation of marketing | Estimated renewal date |
---|---|---|---|---|
Resumption of marketing | 23.08.2022 | |||
Interruption of marketing | 12.08.2022 |
0107681, 0139063, 0139065, 0139066 |
Capacity/distribution reasons | 23.09.2022 |
Resumption of marketing | 04.09.2020 | |||
Interruption of marketing | 27.07.2020 |
0107681, 0139063, 0139065, 0139066 |
Capacity/distribution reasons | 36. týden |
Resumption of marketing | 08.04.2020 | |||
Interruption of marketing | 06.04.2020 |
0107681, 0139063, 0139065, 0139066 |
Capacity/distribution reasons | 17. týden |
Resumption of marketing | 09.10.2019 | |||
Interruption of marketing | 11.09.2019 |
0107681, 0139063, 0139066 |
Capacity/distribution reasons | 39. týden |
Resumption of marketing | 07.05.2019 | |||
Interruption of marketing | 29.04.2019 |
0107681, 0139063, 0139065, 0139066 |
Capacity/distribution reasons | 20. týden |
Resumption of marketing | 16.01.2017 | |||
Interruption of marketing | 12.01.2017 |
0139063, 0139065, 0139066 |
||
Resumption of marketing | 11.08.2014 | |||
Interruption of marketing | 20.09.2011 |
0107681 |
||
Placing on the market | 01.02.2008 | |||
Resumption of marketing | 01.09.2011 | |||
Interruption of marketing | 02.08.2011 | lék v jiné lékové formě |
All reports are available in the Overview.